[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Recursion Pharmaceuticals Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100481726","phase-1-evaluate-rec-4881-in-participants-with-familial-adenomatous-polyposis-fap-100481726",false,"NCT05552755","Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)","A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokintetics, and Pharmacodynamics of REC-4881 in Patients With Familial Adenomatous Polyposis (FAP)","TUPELO","Inclusion Criteria:\n\n1. Male or female and ≥ 18 years of age\n2. Have provided written informed consent to participate in the study\n3. Diagnosis of phenotypic classical FAP with disease involvement of the duodenum or the residual colon\u002Frectum\u002Fpouch as the primary disease site.\n4. Genetic diagnosis of FAP with APC gene mutation (Part 2 only).\n5. Has undergone colectomy or subtotal colectomy\n6. Spigelman Classification Stage II or higher.\n7. Investigator\u002FParticipant agrees to leave polyps ≤10 mm unresected during endoscopies performed at Screening and while on study\n8. Have no significant cardiovascular abnormalities at Screening:\n\n   1. Left ventricular ejection fraction \\>50% as determined on screening echocardiogram (ECHO)\u002F multi-gated acquisition (MUGA)\n   2. A QT interval corrected for heart rate using the Fridericia formula (QTcF) \\\u003C 450 msec in men and \\\u003C470 milliseconds (msec) in women.\n9. Have no significant hematopoietic abnormalities at Screening:\n\n   1. White blood cell count (WBC) ≥ 3,000\u002Fcubic millimeters (mm\\^3) (non-black populations); 2,700\u002Fmm\\^3 (black populations)\n   2. Platelet count ≥ 120,000\u002Fmm\\^3\n   3. Hemoglobin ≥ 10.0 grams (g)\u002Fdeciiter (dL)\n   4. No history of clinical coagulopathy.\n10. Have no significant hepatic abnormalities at Screening:\n\n    1. Total bilirubin ≤ 1.5 \\* upper limit of normal (ULN) (individuals with Gilbert syndrome may be enrolled)\n    2. Aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) ≤ 2.0 \\* ULN.\n11. Have no significant renal abnormalities at Screening: serum creatinine ≤ 1.5 times \\* ULN.\n12. Female participants who are women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours before the first dose of study drug. If the urine test is positive or cannot be confirmed negative, a serum pregnancy test will be required and must be negative for the participant to be eligible.\n13. All participants must be willing to follow the contraceptive guidance in the protocol and must not be lactating or planning to attempt to become pregnant during the study or for a further period of 4 months after the last dose of study drug or impregnate someone during this study or for a further period of 14 weeks after the last dose of study drug.\n14. Absence of gross blood in stool at Screening; red blood on toilet paper only is acceptable.\n15. Participant must be willing to discontinue use of non-steroidal anti-inflammatory agents (NSAIDs) 6 weeks prior to Study Day 1 and remain off NSAIDs throughout the treatment period of the study (use of aspirin ≤ 700 milligrams \\[mg\\] week is allowed.)\n\nExclusion Criteria:\n\n1. Has any clinically significant laboratory abnormality, medical or psychiatric illness which, in the opinion of the Investigator, could interfere with the conduct or interpretation of the study or put the participant at risk.\n2. Has had prior pelvic irradiation.\n3. Has gastrointestinal disease or recent gastrointestinal procedure that could interfere with oral absorption of REC-4881, including difficulty swallowing capsules.\n4. Has received treatment with other investigational agents within the 4 weeks prior to Study Day 1 or a period during which the investigational agent has not been cleared from the body (that is, at least a period of 5 half-lives, if known), whichever is longer.\n5. Treatment with other FAP-directed drug therapy (such as off-label use of Balsalazide) within 8 weeks of screening endoscopy (Part 2 only) or had a Whipple procedure.\n6. Is currently under treatment for desmoid tumors.\n7. Use of omega-3 fatty acids or oral corticosteroids prior to Study Day 1\n8. Use of strong cytochrome P3A (CYP3A) inhibitors or inducers prior to Study Day 1\n9. History of an ongoing or newly diagnosed eye abnormality, including:\n\n   1. Retinal pathologies such as diabetic retinopathy, veno-occlusion, or macular edema\n   2. Corneal pathologies such as herpes keratitis, corneal dystrophy, corneal erosions, corneal degeneration, active or recurrent keratitis, or uveitis (intermittent, posterior, and\u002For panuveitis)\n   3. Other clinically significant ophthalmologic abnormalities (for example, retinal detachment) or has findings at Screening. \\[Participants with corrected myopia may be enrolled.\\]\n10. Has cancer at screening endoscopy in gastrointestinal (GI) tract (including stomach, duodenum, and colon\u002Frectum\u002Fpouch) (Part 2 only).\n11. Has a large polyp (\\>1 centimeter \\[cm\\]) not amenable to complete removal\n12. Has active pancreatitis secondary to pancreatic duct obstruction\n13. Has active gall bladder disease\n14. Is pregnant, lactating or is planning to attempt to become pregnant during this study or within 4 months after the last dose of study drug (women) or is planning to attempt to impregnate someone or donate sperm during the study or within 14 weeks after the last dose of study drug (men).\n15. Has had major surgery prior to Study Day 1\n16. Has an active infection requiring systemic therapy.\n17. Has known hypersensitivity to the study drug or its excipients.\n18. Has a history of alcohol or substance abuse within 1 year prior to screening for study participation, or is currently using alcohol, drugs of abuse, or any prescribed or over-the-counter medication in a manner which, in the opinion of the Investigator, indicates abuse.\n19. Received treatment with another mitogen-activated protein kinase (MEK) inhibitor 8 weeks prior to Screening and throughout the treatment period of the study.\n20. Any of the following known active infections:\n\n    1. Human immunodeficiency virus (HIV) not optimally controlled or treated. Participants with HIV who are on sustained stable antiretrovirals (for \\>4 weeks) and have cluster of differentiation (CD)4+ counts ≥ 350 cells\u002Fmicroliter (μL) may be enrolled. No HIV testing is required unless clinically indicated or mandated by local health authority.\n    2. Chronic hepatitis B virus (HBV) infection with surface antigen positive: participants with a prior history of treated HBV infection who are hepatitis B surface antigen-negative may be enrolled. No testing is required for hepatitis B unless clinically indicated or mandated by local health authority.\n    3. Chronic hepatitis C virus (HCV) infection: untreated or on active treatment. Participants with a prior history of treated HCV infection who are HCV RNA-undetectable may be enrolled. No testing is required for hepatitis C unless clinically indicated or mandated by local health authority.\n21. Has a severe or uncontrolled medical condition (for example, dermatologic disease, etc.) that, in the opinion of the Investigator, would pose a significant clinical risk for the participant.\n22. Use of strong Breast Cancer Resistance Protein (BCRP) or Multidrug Resistance-Associated Protein 2 (MRP2) inhibitors within 14 days of Study Day 1 and throughout the treatment period of the study.\n23. Clinically significant cardiovascular disease ≤ 6 months before first dose\n\n    1. Myocardial infarction or unstable angina\n    2. Clinically significant cardiac arrhythmias\n    3. Uncontrolled hypertension: systolic blood pressure (SBP) \\> 180 millimeters of mercury (mmHg), diastolic blood pressure (DBP) \\> 100 mmHg\n    4. Pulmonary embolism, symptomatic cerebrovascular events or any other serious cardiac condition (for example, pericardial effusion or restrictive cardiomyopathy)\n    5. QTcF prolongation \\>450 msec in males and \\>470 msec in females at screening or history of long QTc syndrome\n    6. Congestive heart failure (New York Heart Association class III-IV)\n    7. Myocarditis \u002F clinically significant pericarditis.\n    8. Atrial enlargement.","ALL","18 Years",{"count":20,"type":21},67,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is a multicenter, two-part trial in participants with FAP.",[28],"Familial Adenomatous Polyposis",[30,31,32,33,34],"FAP","familial adenomatous polyposis","APC mutation","adenomatous polyposis coli","desmoid disease","RECRUITING","2026-06-03",{"date":38,"type":39},"2026-06-05","ACTUAL",{"date":41,"type":39},"2023-07-10",{"date":43,"type":21},"2027-09",{"name":45,"class":46},"Recursion Pharmaceuticals Inc.","INDUSTRY",17,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100568241","phase-1-a-study-of-rec-1245-in-participants-with-unresectable-locally-advanced-or-metastatic-cancer-100568241","NCT06678659","A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","A Phase 1 \u002F 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","DAHLIA","Inclusion Criteria:\n\n* Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed \u002F refractory lymphoma\n* Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.\n* Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70.\n* Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 \u002F Lugano criteria and documented by computed tomography (CT) and \u002F or magnetic resonance imaging (MRI)\n\nExclusion Criteria:\n\n* Received treatment with another RBM39 degrader\n* Clinically significant gastrointestinal (GI) or GI malabsorption","12 Years",{"count":58,"type":21},170,[24,25],"This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.",[62,63,64,65],"Unresectable","Locally Advanced","Metastatic Cancers","Relapsed\u002FRefractory Lymphomas",[67,68,69,64],"RBM39","Cancer","Refractory Lymphomas","2026-05-06",{"date":72,"type":39},"2026-05-08",{"date":74,"type":39},"2024-11-21",{"date":76,"type":21},"2028-10-30",{"name":45,"class":46},6,""]